Novartis to Buy Big Stake in Alnylam as Part Of RNAi Alliance; Deal Could Be Worth $700M
September 09, 2005
Novartis to Buy Big Stake in Alnylam as Part Of RNAi Alliance; Deal Could Be Worth $700M
The collaboration, in which Novartis will gain a 19.9-percent stake in Alnylam, will enable the RNAi company to increase its headcount by more than one-third and continue to operate through 2010. Subscribers: click headline for more
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UniQure, Collaborators Secure $3.2M Eurostar Grant for Huntington’s Disease Effort
May 22, 2013 / Gene Silencing News - Tools & Techniques: TALENs for miRNA Manipulation; CLASH for miRNA-Target Analysis; and More
May 21, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 21, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 21, 2013 / Gene Silencing News - Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News